Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease

Trial Profile

Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy; Hepatic fibrosis; Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
    • 10 Jun 2017 Biomarkers information updated
    • 25 Sep 2015 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top